Sugi Predict

Sugi Predict / Compounds / Salicyladehyde

Salicyladehyde

Salicyladehyde

SCHEMBL1070652

CC(N)CN.O=Cc1ccccc1O.O=Cc1ccccc1O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRIM24 O15164 1/20 0.64
▸ TRIM33 Q9UPN9 1/20 0.64
▸ ERN1 O75460 1/20 0.46
▸ CA2 P00918 5/20 0.43
▸ CA1 P00915 2/20 0.43
▸ TYR P14679 1/20 0.43
▸ CDK4 P11802 1/20 0.43
▸ CCND1 P24385 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CA12 O43570 3/20 0.39
▸ NFKB1 P19838 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicyladehyde SCHEMBL10428023 1.00 TRIM24 (0.64) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL29268392 0.98 TRIM24 (0.62) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL10428032 0.89 TRIM24 (0.64) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL27867603 0.85 TRIM24 (0.75) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL27744705 0.83 TRIM24 (0.60) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL3379351 0.83 TRIM24 (0.78) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL531267 0.83 TRIM24 (0.78) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL27791581 0.82 TRIM24 (0.86) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL28475111 0.82 TRIM24 (0.64) TRIM24TRIM33ERN1CA2CA1
Salicyladehyde SCHEMBL8035808 0.81 TRIM24 (0.58) TRIM24TRIM33ERN1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113563287-A Preparation method of epoxy caprylate and preparation method of melonal 山东新和成药业有限公司 2021-10-29 — — CN claimed
US-20240050365-A1 STABLE SOLID FINGOLIMOD DOSAGE FORMS HANDA NEUROSCIENCE, LLC (US) 2024-02-15 — — US disclosed
US-20230149302-A1 STABLE SOLID FINGOLIMOD DOSAGE FORMS HANDA NEUROSCIENCE, LLC (US) 2023-05-18 — — US disclosed
CN-113563287-B Preparation method of epoxy caprylate and preparation method of melonal 山东新和成药业有限公司 2023-04-07 — — CN disclosed
CN-111566178-B Propylene-based polymer-based hot melt adhesive composition and method of using same 波士胶公司 2022-11-01 — — CN disclosed
CN-110337363-B Styrene-based material for hot melt adhesives 波士胶公司 2022-01-11 — — CN disclosed
CN-113563287-A Preparation method of epoxy caprylate and preparation method of melonal 山东新和成药业有限公司 2021-10-29 — — CN disclosed
US-11154625-B2 Fucoidans as ligands for the diagnosis of degenerative pathologies INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2021-10-26 — — US disclosed
CN-113543758-A Humidity indicator free of halogen-containing substances 波士胶公司 2021-10-22 — — CN disclosed
US-20210169793-A1 STABLE SOLID FINGOLIMOD DOSAGE FORMS HANDA NEUROSCIENCE, LLC (US) 2021-06-10 — — US disclosed
WO-1994016741-A1 IMMUNOREACTIVE REAGENTS EMPLOYING HETERODIMERS THE WELLCOME FOUNDATION LIMITED (GB) 1994-08-04 — — WO disclosed
WO-1994013327-A1 IMMUNOREACTIVE REAGENTS EMPLOYING DIHYDROFOLATE REDUCTASE THE WELLCOME FOUNDATION LIMITED (GB) 1994-06-23 — — WO disclosed
WO-1994012216-A1 SEQUENTIAL TARGETING OF TUMOR SITES WITH OLIGONUCLEOTIDE CONJUGATES OF ANTIBODY AND COMPLEMENTARY OLIGONUCLEOTIDE CONJUGATES OF CHELATED RADIONUCLIDE THE WELLCOME FOUNDATION LIMITED (GB) 1994-06-09 — — WO disclosed
WO-1994008624-A2 THERAPEUTIC AND DIAGNOSTIC IMAGING COMPOSITIONS AND METHODS STERLING WINTHROP INC. (US) 1994-04-28 — — WO disclosed
WO-1994008629-A1 MR IMAGING COMPOSITIONS, BASED ON POLY(ALKYLENEOXIDE) STERLING WINTHROP INC. (US) 1994-04-28 — — WO disclosed
WO-1994009056-A1 CHELATING POLYMERS STERLING WINTHROP INC. (US) 1994-04-28 — — WO disclosed
US-5246073-A Injecting crosslinkable polymers or the monomers therof, crosslinking agent, buffering agent and water UNION OIL COMPANY OF CALIFORNIA (US) 1993-09-21 — — US disclosed
US-5225340-A Bacterial digestion NALCO CHEMICAL COMPANY (US) 1993-07-06 — — US disclosed
US-4758415-A Process for removing soluble metal cations in iron oxide pigments BASF CORPORATION (US) 1988-07-19 — — US disclosed
US-4017303-A Manufacture of acicular ferromagnetic metal pigments containing iron BASF AKTIENGESELLSCHAFT (DT) 1977-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210169793-A1 STABLE SOLID FINGOLIMOD DOSAGE FORMS S1PR4, S1PR2, S1PR5 TRIM24 1125/4885TRIM33 626/4885ERN1 4667/4885
US-20240050365-A1 STABLE SOLID FINGOLIMOD DOSAGE FORMS S1PR4, S1PR2, S1PR5 TRIM24 1125/4885TRIM33 626/4885ERN1 4667/4885
US-20230149302-A1 STABLE SOLID FINGOLIMOD DOSAGE FORMS S1PR4, S1PR2, S1PR5 TRIM24 1136/4885TRIM33 623/4885ERN1 4676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.